Cynosure, Inc.

Pharmaceutical firms collaborate in trial of dermatology product

Published in Drug Law Weekly, June 15th, 2004

Cynosure, Inc., a developer and manufacturer of lasers and pulsed light sources, announced that it will collaborate with DU.S.A Pharmaceuticals, Inc., as the exclusive provider of the V-Star pulse dye laser systems for DU.S.A's phase II clinical study for the treatment of facial photodamage.

The trial will use DU.S.A's Levulan photodynamic therapy (PDT) with three light sources, including Cynosure's V-Star pulse dye laser treatment.

"Leading dermatologists consider Levulan PDT one of the most exciting developments impacting their medical and aesthetic practices," said Michael R. Davin, CEO of Cynosure. "As our population ages, the interest in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2004-06-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry